JP2005518332A - 細胞表面のプロテアーゼにより活性化される結合体およびその治療的使用 - Google Patents

細胞表面のプロテアーゼにより活性化される結合体およびその治療的使用 Download PDF

Info

Publication number
JP2005518332A
JP2005518332A JP2002592470A JP2002592470A JP2005518332A JP 2005518332 A JP2005518332 A JP 2005518332A JP 2002592470 A JP2002592470 A JP 2002592470A JP 2002592470 A JP2002592470 A JP 2002592470A JP 2005518332 A JP2005518332 A JP 2005518332A
Authority
JP
Japan
Prior art keywords
seq
arg
ser
therapeutic
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002592470A
Other languages
English (en)
Japanese (ja)
Inventor
エドウィン・エル・マディソン
ジョゼフ・エドワード・センプル
ジョージ・ピー・ブラスク
スコット・ジェフリー・ケンプ
マラレディ・コマンドラ
ダニエル・バナ・シーブ
Original Assignee
デンドレオン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デンドレオン コーポレイション filed Critical デンドレオン コーポレイション
Publication of JP2005518332A publication Critical patent/JP2005518332A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
JP2002592470A 2001-05-23 2002-05-23 細胞表面のプロテアーゼにより活性化される結合体およびその治療的使用 Withdrawn JP2005518332A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29326701P 2001-05-23 2001-05-23
PCT/US2002/016819 WO2002095007A2 (fr) 2001-05-23 2002-05-23 Conjugues actives par des proteases de surface cellulaire et leurs utilisations therapeutiques

Publications (1)

Publication Number Publication Date
JP2005518332A true JP2005518332A (ja) 2005-06-23

Family

ID=23128397

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002592470A Withdrawn JP2005518332A (ja) 2001-05-23 2002-05-23 細胞表面のプロテアーゼにより活性化される結合体およびその治療的使用

Country Status (5)

Country Link
EP (1) EP1545572A4 (fr)
JP (1) JP2005518332A (fr)
KR (1) KR20040004642A (fr)
CA (1) CA2447023A1 (fr)
WO (1) WO2002095007A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012023476A1 (fr) 2010-08-18 2012-02-23 独立行政法人産業技術総合研究所 Procédé de fabrication de film mince à semi-conducteurs organiques et film mince à semi-conducteurs organiques monocristallins

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
EP1544304A4 (fr) * 2002-07-31 2006-05-10 Astellas Pharma Inc Serine protease
JP5335191B2 (ja) 2003-08-22 2013-11-06 デンドレオン コーポレイション Ｔｒｐ−ｐ８発現に関連する疾患の処置をするための組成物および方法
EP1831370A4 (fr) 2004-12-13 2009-08-12 Alethia Biotherapeutics Inc Sequences polynucleotidiques et polypeptidiques participant au remodelage osseux
KR101393946B1 (ko) 2005-10-21 2014-05-12 카탈리스트 바이오사이언시즈, 인코포레이티드 보체 활성화를 억제하는 변형된 프로테아제
US7772266B2 (en) 2006-02-15 2010-08-10 Dendreon Corporation Small-molecule modulators of TRP-P8 activity
CN101420942B (zh) 2006-02-15 2014-03-12 登德雷恩股份有限公司 Trp-p8活性的小分子调节剂
KR100906145B1 (ko) * 2006-05-30 2009-07-03 한국생명공학연구원 Ｔｍｐｒｓｓ4 억제제를 유효성분으로 포함하는 항암제
KR101778174B1 (ko) 2006-07-05 2017-09-13 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP2353609A1 (fr) 2010-02-04 2011-08-10 Sanofi Pasteur Compositions et procédés d'immunisation
US9869021B2 (en) 2010-05-25 2018-01-16 Aventa Technologies, Inc. Showerhead apparatus for a linear batch chemical vapor deposition system
EP2814807A4 (fr) * 2012-02-16 2015-10-07 Rqx Pharmaceuticals Inc Antibiotiques à peptide linéaire
SG11201500412TA (en) 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions
US20150265695A1 (en) 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
MX365612B (es) 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
RU2737434C2 (ru) 2013-03-13 2020-11-30 Форма Терапьютикс, Инк. Новые соединения и композиции для ингибирования fasn
AU2017273857B2 (en) 2016-06-01 2021-08-19 Athira Pharma, Inc. Compounds
US10781435B2 (en) 2017-06-22 2020-09-22 Catalyst Biosciences, Inc. Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
EP3932935A1 (fr) * 2020-06-29 2022-01-05 Centre National de la Recherche Scientifique Peptides antibactériens

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972616A (en) * 1998-02-20 1999-10-26 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
EP1161266A4 (fr) * 1999-03-12 2007-09-19 Univ Georgetown Matriptase, protease de la serine, et son utilisation
WO2001036604A2 (fr) * 1999-11-18 2001-05-25 Corvas International, Inc. Acides nucleiques codant pour des endotheliases, endotheliases et leurs utilisations
EP1263473A2 (fr) * 2000-03-15 2002-12-11 Bristol-Myers Squibb Pharma Company Medicaments antineoplastiques cibles pouvant etre clives par la peptidase et utilisation therapeutique de ces medicaments
CA2451188A1 (fr) * 2001-06-25 2003-01-03 Drug Innovation & Design, Incorporated Ciblage cellulaire faisant appel a la reconnaissance des formes exponentielle, compositions, procedes et applications anticancereuses
WO2003037326A1 (fr) * 2001-10-29 2003-05-08 Corvas International, Inc. Synthese en phase solide de chimiotheques
JP2006503545A (ja) * 2002-02-14 2006-02-02 ラター， ウィリアム ジェイ． 処置される宿主における切断についてのキメラ分子
AU2003269880A1 (en) * 2002-05-21 2003-12-22 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012023476A1 (fr) 2010-08-18 2012-02-23 独立行政法人産業技術総合研究所 Procédé de fabrication de film mince à semi-conducteurs organiques et film mince à semi-conducteurs organiques monocristallins
US9059407B2 (en) 2010-08-18 2015-06-16 National Institute Of Advanced Industrial Science And Technology Method for manufacturing organic semiconductor thin film and monocryastalline organic semiconductor thin film

Also Published As

Publication number Publication date
KR20040004642A (ko) 2004-01-13
EP1545572A2 (fr) 2005-06-29
WO2002095007A2 (fr) 2002-11-28
WO2002095007A3 (fr) 2005-05-06
CA2447023A1 (fr) 2002-11-28
EP1545572A4 (fr) 2006-04-12

Similar Documents

Publication Publication Date Title
JP2005518332A (ja) 細胞表面のプロテアーゼにより活性化される結合体およびその治療的使用
US20040001801A1 (en) Conjugates activated by cell surface proteases and therapeutic uses thereof
JP3481948B2 (ja) 新規ペプチド
US5948750A (en) Conjugates useful in the treatment of prostate cancer
US6391305B1 (en) Conjugates useful in the treatment of prostate cancer
JP3607201B2 (ja) Ｆａｐ活性化抗腫瘍性化合物
AU726434B2 (en) Conjugates useful in the treatment of prostate cancer
EP1144011B1 (fr) Composes de promedicaments et procede de preparation
AU715632B2 (en) Conjugates useful in the treatment of prostate cancer
US20150314014A1 (en) Inhibitor which is deactivatable by a reagent produced by a target cell
JP2003526683A (ja) ペプチダーゼ切断可能な標的抗新生物薬およびそれらの治療への使用
US5998362A (en) Conjugates useful in the treatment of prostate cancer
US20070021350A1 (en) Conjugates useful in the treatment of prostate cancer
AU708475B2 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
US6174858B1 (en) Conjugates useful in the treatment of prostate cancer
US20030232760A1 (en) Conjugates useful in the treatment of prostate cancer
US20070129309A1 (en) Conjugates useful in the treatment of prostate cancer
US20020115596A1 (en) Conjugates useful in the treatment of prostate cancer
US20030133927A1 (en) Conjugates useful in the treatment of prostate cancer
US20050119166A1 (en) Conjugates useful in the treatment of prostate cancer
US20040058857A1 (en) Method of treating cancer
GB2545169B (en) Taxane Prodrug Comprising A Membrane Type Matrix Metalloproteinase Cleavage Site
AU2002312119A1 (en) Conjugates activated by cell surface proteases and therapeutic uses thereof
AU714288B2 (en) Novel peptides
US20020173451A1 (en) Method of treating cancer

Legal Events

Date Code Title Description
A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060302